Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Boston Scientific paidMXN0 Mil more to buy back shares than it received from issuing new shares.
It spentMXN4,670 Mil paying down its debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0 Mil from paying cash dividends to shareholders.
It spentMXN18 Mil on other financial activities.
In all, Boston ScientificspentMXN4,689 Mil on financial activities for the
three
months ended in Mar. 2026.
Boston Scientific (MEX:BSX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Boston Scientific's issuance of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Boston Scientific's repurchase of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Boston Scientific's net issuance of debt for the
three
months ended in Mar. 2026 was MXN-4,670 Mil.
Boston Scientific spentMXN4,670 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Boston Scientific's net issuance of preferred for the
three
months ended in Mar. 2026 was MXN0 Mil.
Boston Scientific paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Boston Scientific's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN0 Mil.
Boston Scientific receivedMXN0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Boston Scientific's other financing for the
three
months ended in Mar. 2026 was MXN-18 Mil.
Boston Scientific spentMXN18 Mil on other financial activities.
Boston Scientific Cash Flow from Financing Related Terms
Boston Scientific Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Boston Scientific's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-16,311 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN-16,311 Mil mean?
Boston Scientific (MEX:BSX) has a Cash Flow from Financing of MXN-16,311 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Boston Scientific and its competitors.
Is Boston Scientific's Cash Flow from Financing too high?
Boston Scientific's current Cash Flow from Financing is MXN-16,311 Mil. Overall, Boston Scientific has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Cash Flow from Financing compare to EW and DXCM?
Boston Scientific's Cash Flow from Financing of MXN-16,311 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Boston Scientific and its competitors. Boston Scientific's current Cash Flow from Financing is MXN-16,311 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,842.10, compared to a current price of MXN775.01 — trading 57.9% below its estimated fair value. The current Cash Flow from Financing is MXN-16,311 Mil. Boston Scientific's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Cash Flow from Financing is MXN-16,311 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN775.01 is trading 57.9% below its estimated GF Value™ of MXN1,842.10.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
Cash Flow from Financing: MXN-16,311 Mil
GF Value™: MXN1,842.10 vs. price of MXN775.01 (57.9% below fair value)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
83GF Score
Get the complete analysis for MEX:BSX
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
